Mr Cooper Group Inc (COOP): I agree with you. If the money is comin...

dimples52 · 2019-12-23T17:48:01.5930000Z

I agree with you. If the money is coming from outside of the LT then they have had years to get everything setup and ready to distribute immediately. It's ridiculous to think that we have to continue to wait weeks or months more. We have already been waiting 11 years.

Play Episode

6min

Proactive - Interviews for investors

Pinnacle Silver & Gold eyes near-term production at high-grade El Potrero project in Mexico

Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:NRGOF) president and CEO Robert Archer talked with Proactive's Stephen Gunnion about the company’s latest acquisition, the El Potrero mine in Mexico. Archer explained that the company is focused on fast-tracking the project towards production within two to three years, aiming to build the business through cash flow rather than relying on external markets. El Potrero was previously in production in the late 1980s, with existing underground workings and a 100-ton-per-day processing plant. Archer highlighted that much of the infrastructure remains in place, which should help streamline redevelopment efforts at a relatively low cost. The company plans to rehabilitate the underground workings, conduct systematic sampling, and commence drilling to establish a resource base sufficient to restart production. On the financial side, Pinnacle Silver recently raised $800,000 in a private placement, with plans to secure up to $2–$3 million over the next few years to fully fund the restart. Archer also shared insights from the PDAC conference, noting positive sentiment around metals despite broader economic uncertainties. The company expects a strong news flow this year as exploration and development efforts accelerate. For more updates, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for the latest news. #Mining #Gold #Silver #PinnacleSilver #MexicoMining #ResourceStocks #JuniorMining #GoldInvestment #MiningExploration #PreciousMetals

Proactive - Interviews for investors

GoviEx Uranium CEO on Muntanga feasibility study milestone and market dynamics

GoviEx Uranium CEO Daniel Major talked with Proactive's Stephen Gunnion about the company’s latest milestone—the completion and filing of the feasibility study for its Muntanga Uranium Project in Zambia. Major explained that the study underscores the project's simplicity, highlighting its open-pit heap leaching operation, low technical risk, and strong economics. GoviEx is targeting production by 2028, with financial preparations already in progress. The company has appointed Endeavor Financial to lead the debt financing process and has begun outreach to potential lenders. Meanwhile, environmental approvals are expected by year-end, paving the way for construction. Discussing uranium market dynamics, Major pointed to a growing supply deficit and increasing demand from utilities. Despite market uncertainties, term contracts remain strong at around $80 per pound. He also noted shifting supply chains, with African uranium playing a more prominent role due to restrictions on Russian and Kazakh supply. "The market needs these projects," Major stated. "GoviEx with Muntanga is one of those projects that can come in and support and fill that gap." Watch the full interview for more insights. Don’t forget to like the video, subscribe to our channel, and turn on notifications for future updates. #GoviExUranium #UraniumMining #MuntangaProject #ZambiaMining #NuclearEnergy #UraniumMarket #MiningStocks #EnergyTransition #UraniumSupply #Investing

Proactive - Interviews for investors

Solvonis Therapeutics strengthens board with addition of Dr Renata Crome

Solvonis Therapeutics PLC (LSE:SVNS) non-executive director-elect Dr Renata Crome talked with Proactive about her appointment to the board and what she brings to the company. Dr Crome has an extensive background in pharmaceutical development, having worked at Roche for 30 years. She played a key role in the development of blockbuster treatments such as bevacizumab and obinutuzumab for cancer, as well as Tamiflu for influenza. Following her time at Roche, she transitioned to board roles across commercial and charity organisations and also lectures in pharmaceutical medicine. Discussing her contributions to Solvonis, Dr Crome highlighted her strategic expertise and experience in central nervous system (CNS) treatments. "I have extensive experience in developing treatments in the central nervous system area, and I know the challenges and some of the solutions," she said. She also emphasised her ability to leverage a strong network of experts to support the company's goals. Dr Crome expressed enthusiasm for Solvonis' innovative pipeline and differentiated treatments, as well as the strength of its leadership team. "It’s a privilege to be invited to join them," she said. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #SolvonisTherapeutics #Pharmaceuticals #Biotech #HealthcareInnovation #Leadership #CNSResearch #DrugDevelopment #Investing #Biopharma #ExecutiveLeadership

Proactive - Interviews for investors

Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data

Immunic Therapeutics chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company's strong presence at the 10th annual ACTRIMS Forum, where it presented two key posters on multiple sclerosis (MS). He highlighted that Immunic’s investigational drug, vidofludimus calcium, has potential neuroprotective properties that may benefit both relapsing and progressive MS patients. One of the posters examined baseline characteristics of past progressive MS trials and contrasted them with Immunic’s CALLIPER trial, designed for non-relapsing patients with minimal inflammatory activity. The second poster explored preclinical data on the drug’s mechanism of action, emphasizing its potential to target activated microglia and support neuron survival. Muehler noted significant engagement from the MS community at ACTRIMS, with many keenly anticipating the CALLIPER trial’s readout in April. “It’s really one of the very few late-stage drugs with a potential neuroprotective effect,” he said, adding that the data could provide new hope for progressive MS patients who currently have limited treatment options. Stay tuned for more updates on Immunic’s progress. For more interviews, subscribe to Proactive’s YouTube channel, like this video, and turn on notifications! #ImmunicTherapeutics #MSResearch #Neuroprotection #CALLIPERTrial #MultipleSclerosis #Biotech #DrugDevelopment #ClinicalTrials #MedicalBreakthrough #ACTRIMS

Followers	6
Posts	462
Boards Moderated	0
Alias Born	10/26/2011

Volume:	564,731
Day Range:	99.15 - 101.68
Bid:	89.00
Ask:	107.70
Last Trade Time:	5:30:30 PM EDT
Total Trades:	11,634

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

COOP Detailed Quote

Recent COOP News

More COOP News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent COOP News

Go Ad-Free